On May 27, 2025 OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, reported that three of its research abstracts have been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 31–June 4 in Chicago, Illinois (Press release, OncoHost, MAY 27, 2025, View Source [SID1234653414]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The selected studies span multiple cancer types—including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and ovarian cancer—highlighting the broad clinical utility of plasma proteomics and the company’s continued commitment to advancing personalized treatment strategies through host-response biomarker innovation.
Poster Presentations
Title: Longitudinal Plasma Proteomic Analysis: A Monitoring Strategy for NSCLC Patients Treated with Immunotherapy
Presenter: Yehonatan Elon, PhD, CTO at OncoHost
Session Date: May 31, 2025 | 1:30 PM CDT | Hall A – Posters and Exhibits
Abstract Number: 8579 | Poster Board: 59
This study explores the use of plasma proteomic signatures to dynamically monitor treatment response in NSCLC patients receiving immune checkpoint inhibitors (ICIs). The research identified three distinct proteomic patterns—reflecting drug presence, immune activation, and lung tissue damage—and demonstrated their potential for early identification of non-responders up to 6.6 months before radiologic imaging. A comparative analysis with ctDNA will also be presented.
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
Title: A Plasma Proteomics-Based Model for Predicting Response to Neoadjuvant Chemotherapy in Ovarian Cancer
Presenter: Ofer Sharon, MD, CEO at OncoHost
Session Date: June 2, 2025 | 1:30 PM CDT | Hall A – Posters and Exhibits
Abstract Number: 3056 | Poster Board: 371
This research presents a novel computational model based on pre-treatment plasma proteomics that predicts chemotherapy response in high-grade serous ovarian cancer (HGSOC). The study demonstrates the feasibility of using plasma proteomics from pre-treatment blood samples to predict response to neoadjuvant chemotherapy in HGSOC.
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
Title: Genomic and Proteomic Predictors of Sites of Metastases in Renal Cell Carcinoma
Presenter: Clara Steiner, MD, Postdoctoral Research Fellow at Dana-Farber Cancer Institute
Session Date: June 2, 2025 | 9:00 AM CDT | Hall A – Posters and Exhibits
Abstract Number: 4538 | Poster Board: 338
Through multi-omics profiling of metastatic RCC patients, this study identifies genomic alternations and circulating proteins associated with specific metastatic sites, including lung, bone, and liver. These findings support the development of non-invasive predictors of metastatic organotropism and may inform future site-specific treatment strategies.
The abstract is available on the ASCO (Free ASCO Whitepaper) website here.
"Our expanding clinical pipeline and participation in ASCO (Free ASCO Whitepaper) 2025 represent critical milestones in the evolution of precision oncology," said Ofer Sharon, MD, CEO of OncoHost. "By combining advanced proteomic technologies with AI-driven analytics, we continue to demonstrate the versatility of our platform across tumor types and treatment settings—reinforcing our commitment to amplifying oncologist’s insights in making more personalized and effective treatment decisions."